Related content

Reply to Dr. Mégarbane et al. regarding “Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose”

By Isbister Geoffrey   Friberg Lena   Duffull Stephen  

Intensive Care Medicine, Vol. 33, Iss. 1, 2007-01 ,pp. : 197-197

Springer Publishing Company

Access to resources Recommend Favorite

In response to Isbister et al.: Application of pharmacokinetic–pharmacodynamic modeling in management of QT abnormalities after citalopram overdose

By Manini Alex   Smith Silas   Moskovitz Joshua   Nelson Lewis  

Intensive Care Medicine, Vol. 33, Iss. 4, 2007-04 ,pp. : 738-738

Springer Publishing Company

Access to resources Recommend Favorite

Application of pharmacokinetic-pharmacodynamic modeling in management of QT abnormalities after citalopram overdose. Reply to A. Manini

By Isbister Geoffrey   Friberg Lena   Duffull Stephen  

Intensive Care Medicine, Vol. 33, Iss. 4, 2007-04 ,pp. : 739-739

Springer Publishing Company

Access to resources Recommend Favorite

Population pharmacokinetic‐pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 91-2700, Iss. 11, 2015-11 ,pp. : 1236-1247

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetic‐pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 11, 2015-11 ,pp. : 1236-1247

John Wiley & Sons Inc

Access to resources Recommend Favorite